Damtix 500 mg/100 mg spot-on solution for dogs over 4 kg up to 10 kg

Authorised

- Imidacloprid
- Permethrin (40:60)

Product identification

Medicine name:
Damtix 500 mg/100 mg spot-on solution for dogs over 4 kg up to 10 kg

Active substance:
Imidacloprid

Permethrin (40:60)

Target species:
Dog

Route of administration:
Spot-on use

Product details

Active substance and strength:
Imidacloprid
100.00 milligram(s) / 1.00 Pipette

Permethrin (40:60)
500.00 milligram(s) / 1.00 Pipette

Pharmaceutical form:
Spot-on solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP53AC54

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Italy

Package description:
White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 3 ml pipette containing 1.0 ml of solution Box containing 1 pipette
White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 3 ml pipette containing 1.0 ml of solution Box containing 3 pipettes
White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 3 ml pipette containing 1.0 ml of solution Box containing 4 pipettes
White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 3 ml pipette containing 1.0 ml of solution Box containing 6 pipettes
White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 3 ml pipette containing 1.0 ml of solution Box containing 10 pipettes

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:
1/05/2023

Manufacturing sites for batch release:
KRKA tovarna zdravil d.d. Novo mesto

Responsible authority:
Ministry Of Health

Authorisation number:
105613

Date of authorisation status change:
1/05/2023

Reference member state:
Ireland

Procedure number:
IE/V/0663/002

Concerned member states:
Finland France Germany Greece Italy Portugal Spain

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 6/07/2025
Download

Summary of Product Characteristics